VolitionRx raises $7.525M in public offering of 4.3M shares plus full over-allotment

VOLITIONRX LTD

Gross proceeds $7.525M from 4,300,000 shares at $1.75/share; net ~$8.0M after underwriting discount.
Underwriter exercised option for 645,000 additional shares, bringing total to 4,945,000 shares.
Proceeds to fund R&D, clinical studies, product commercialization, working capital, and potential acquisitions.
Preliminary unaudited cash and equivalents of ~$10.9M as of Dec 31, 2022.
Offering led by Newbridge Securities; closed Feb 22, 2023.

item 1.01 item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

VOLITIONRX LTD entered into Underwriting Agreement with Newbridge Securities Corporation (effective 2023-02-17).

Action: entry
Agreement: underwriting
Counterparty: Newbridge Securities Corporation
Effective: 2023-02-17

Exact text from the filing

On February 17, 2023, VolitionRx Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”) pursuant to which the Company agreed to issue and sell an aggregate of 4,300,000 shares

View on SEC.gov

Browse all material agreements →

VOLITIONRX LTD filing history →

Source: SEC EDGAR

accession 0001477932-23-001176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.